MedTrace Logo

MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma

NCT06141096 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2023-11-21

No results posted yet for this study

Summary

A randomized, open, multicenter clinical trial design was adopted, planned to be conducted in three stages, with 91 participants expected to be included in the study to evaluate the efficacy, tolerance, and safety of different doses of MB07133 in the treatment of unresectable advanced primary liver cancer.

Conditions

  • Safety Issues
  • Effect of Drug
  • Tolerance

Interventions

DRUG

MB07133

Evaluate the effectiveness and safety of different doses of MB07133

Sponsors & Collaborators

  • The First Hospital of Jilin University

    collaborator OTHER

  • Xi'an Xintong Pharmaceutical Research Co.,Ltd.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-17
Primary Completion
2024-06-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06141096 on ClinicalTrials.gov